Stock: Boston Scientific (NYSE:BSX) Q4 CY2025 Revenue in Line with Expectations, EPS Beat Consensus

[Para 1: The Lead] Boston Scientific (NYSE:BSX) reported Q4 CY2025 revenue of $5.29 billion, up 15.9% year-over-year, meeting Wall Street expectations. The company's non-GAAP EPS of $0.80 exceeded analysts' consensus by 2.4%. Boston Scientific guided for next quarter's revenue to be around $5.19 billion, close to forecasts. [Para 2-3: Supporting details & Context] Boston Scientific, a global medical device leader, saw its organic revenue grow 16.1% annually over the last two years, outpacing its five-year trend. The company's operating margin expanded by 7.9 percentage points over the past five years, indicating cost efficiency and profitability. EPS grew at a 25.8% CAGR over the last five years, higher than its revenue growth, suggesting improved profitability per share. Boston Scientific's strong performance in Q4 CY2025, with revenue and EPS exceeding expectations, signals continued momentum and market confidence in its growth trajectory.